---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016195"
form_type: "8-K"
ticker: null
cik: "0001261249"
company_name: "AGILE THERAPEUTICS INC"
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:17:36.278420+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Agile Therapeutics receives Nasdaq delisting notice for failing stockholder equity compliance

## Summary
- Nasdaq notified Agile (AGRX) on Sept 27, 2023 that it failed to comply with $2.5M equity rule extension; delisting to proceed unless appealed.
- Agile intends to request a hearing before Nasdaq Hearings Panel, which will stay delisting pending outcome.
- Panel may grant up to 180 additional days (until March 25, 2024) to regain compliance; no assurance of success.
- Delisting could significantly reduce liquidity, market price, and ability to raise capital for the company.

## SEC filing metadata
- accession: 0001558370-23-016195
- form_type: 8-K
- cik: 0001261249
- company_name: AGILE THERAPEUTICS INC
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1261249/000155837023016195/0001558370-23-016195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1261249/000155837023016195/agrx-20230927x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016195
- JSON: https://secwatch.observer/filing/0001558370-23-016195.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016195.txt

## Key facts
- Listing & Compliance Notices
  AGILE THERAPEUTICS INC received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: September 27, 2023, the Company received a notice from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension and that unless the Company requests an appeal, the Staff would proceed with delisting. ​ The Company intends to submit a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. ​ At the Panel hearing, the Company intends to present a plan to regain compliance with the Ru
  evidence_url: https://www.sec.gov/Archives/edgar/data/1261249/000155837023016195/0001558370-23-016195-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.